Bluetooth device to provide better self-care for diabetic patients

London based health startup Patients Pending has announced its new product, a Bluetooth enabled dose capture cap that the company hopes will provide data and more automated care for diabetic patients.

The device, like the original Timesulin smart replacement cap, is compatible with leading insulin pens. The device aims to aid patients and caregivers with data that is not currently available such as personalised dosing support, coaching and patient/clinical communication.

The company intends the new Bluetooth enabled cap to create an intelligent insulin delivery system, which accurately captures dosing data, time and temperature. The information captured will be paired with blood glucose data via an app.

Currently less than 1% of diabetes patients have access to their health data. Patients Pending hope that its new device will make living with the disease simpler, safer and more balanced. The device is now in its final phase of research and development.

CEO and co-founder John Sjölund, who has been living with Type 1 diabetes for over 30 years said: “When insulin and continuous blood glucose data are combined on a smartphone, the resulting possibilities of providing individually personalised dosing and behaviour recommendations – at the right time – is game-changing.  Recent developments within automated insulin delivery systems are hugely exciting, but these advances only affect people using insulin pumps to manage their diabetes and I worry that for the foreseeable future these systems may be out of reach for the overwhelming majority of people globally that choose – or are forced because of cost – to use insulin pens. Our new Timesulin device allows people to keep using the same insulin pen and medicine that they know and trust – whether it comes from companies like Novo Nordisk, Lilly, Sanofi or Biocon – with no prescription or change in routine.”



'Bluetooth device to provide better self-care for diabetic patients' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

© 2018 Rapid Life Sciences Ltd, a Rapid News Communications Group Company. All Rights Reserved.

Privacy policy

Terms and conditions